Deschloroclozapine是一种高亲和力、选择性且代谢稳定的毒蕈碱DREADD激动剂，Deschloroclozapine能快速穿透血脑屏障，有效激活兴奋性hM3Dq和抑制性hM4Di DREADD受体。
Cas No.:1977-07-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Deschloroclozapine is a high-affinity, selective, and metabolically stable muscarinic DREADD agonist. Deschloroclozapine can rapidly cross the blood-brain barrier and effectively activate both excitatory hM3Dq and inhibitory hM4Di DREADD receptors[1-2]. Deschloroclozapine is primarily used in neuroscience for chemogenetic research to precisely modulate neuronal activity[3-4].
In vivo, In transgenic neuropathic pain model rats expressing hM3Dq, subcutaneous injection of Deschloroclozapine (0.1mg/kg) for 120 minutes significantly increased serum OXT levels and rapidly raised the rats' mechanical pain threshold[5]. In transgenic mice expressing hM3Dq, intraperitoneal administration of Deschloroclozapine (1mg/kg) for 5–10 minutes rapidly enhanced neuronal activity via hM3Dq, with an efficacy more than 2.5 times greater than that of Clozapine N-oxide (CNO; 100μg/kg), and brain concentrations of Deschloroclozapine reached approximately 100 nM at 30 minutes[6].
References:
[1] Maggs JL, Williams D, Pirmohamed M, et al. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther. 1995 Dec;275(3):1463-75.
[2] Zhang S, Gumpper RH, Huang XP, et al. Molecular basis for selective activation of DREADD-based chemogenetics. Nature. 2022 Dec;612(7939):354-362.
[3] Nentwig TB, Obray JD, Vaughan DT, et al. Behavioral and slice electrophysiological assessment of DREADD ligand, deschloroclozapine (DCZ) in rats. Sci Rep. 2022 Apr 21;12(1):6595.
[4] Hu F, Morris PJ, Bonaventura J, et al. 18F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. Eur J Med Chem. 2021 Mar 5;213:113047.
[5] Nagai Y, Miyakawa N, Takuwa H, et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nat Neurosci. 2020 Sep;23(9):1157-1167.
[6] Shimizu M, Yoshimura M, Baba K, et al. Deschloroclozapine exhibits an exquisite agonistic effect at lower concentration compared to clozapine-N-oxide in hM3Dq expressing chemogenetically modified rats. Front Neurosci. 2023 Nov 30;17:1301515.
Deschloroclozapine是一种高亲和力、选择性且代谢稳定的毒蕈碱DREADD激动剂，Deschloroclozapine能快速穿透血脑屏障，有效激活兴奋性hM3Dq和抑制性hM4Di DREADD受体[1-2]。Deschloroclozapine主要用于神经科学领域的化学遗传学研究，以精确调控神经元活动[3-4]。
在体内，对表达hM3Dq的转基因的神经病理性疼痛模型大鼠，皮下注射Deschloroclozapine（0.1mg/kg）处理120分钟，Deschloroclozapine显著升高血清OXT浓度，且快速提大鼠的机械痛阈[5]。对表达hM3Dq的转基因小鼠腹腔注射Deschloroclozapine（1mg/kg）处理5-10分钟，Deschloroclozapine通过hM3Dq快速增强神经元活性，效果强度为Clozapine N-oxide（CNO；100μg/kg）的2.5倍以上，且脑内Deschloroclozapine浓度在30分钟时达100nM[6]。
| Animal experiment [1]: | |
|
Animal models |
OXT-hM3Dq-mCherry transgenic rats (adult male). |
|
Preparation Method |
Rats were subcutaneously (s.c.) administered a single dose of Deschloroclozapine (0.1mg/kg). Serum oxytocin (OXT) concentrations were measured at 0, 10, 30, 60, 120, and 180 minutes post-injection. Brain neuronal activity (Fos expression) was assessed 120 minutes post-injection. In a neuropathic pain model (Seltzer model), behavioral tests (von Frey test, Rat Grimace Scale, hot plate test) were conducted at 0, 10, 30, 60, 120, and 180 minutes post-Deschloroclozapine administration. |
|
Dosage form |
0.1mg/kg; s.c.; Single injection. |
|
Applications |
Deschloroclozapine administration induced a rapid and robust increase in serum OXT levels, Deschloroclozapine significantly enhanced neuronal activation (Fos expression) in brain regions including the SON, PVN, and PAG comparable to a 10-fold higher dose of CNO, and produced rapid analgesic effects in a neuropathic pain model (significantly increasing mechanical nociceptive threshold and reducing pain scores within 10 minutes). |
|
References: |
|
| Cas No. | 1977-07-7 | SDF | |
| 别名 | 氯氮平杂质 | ||
| Canonical SMILES | CN1CCN(C2=NC3=CC=CC=C3NC4=CC=CC=C42)CC1 | ||
| 分子式 | C18H20N4 | 分子量 | 292.38 |
| 溶解度 | DMSO: 100 mg/mL (342.02 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4202 mL | 17.101 mL | 34.2021 mL |
| 5 mM | 684 μL | 3.4202 mL | 6.8404 mL |
| 10 mM | 342 μL | 1.7101 mL | 3.4202 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet